BRAF-and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress

Molecular Therapy

Volumn 23, Issue 5, 2015, Pages 931-942

  Roulstone, Victoria ^a   Pedersen, Malin ^a   Kyula, Joan ^a   Mansfield, David ^a   Khan, Aadil A ^a   Mcentee, Grainne ^a   Wilkinson, Michelle ^a   Karapanagiotou, Eleni ^a   Coffey, Matt ^b   Marais, Richard ^c   Jebar, Adel ^d   Errington Mais, Fiona ^d   Melcher, Alan ^d   Vile, Richard ^e   Pandha, Hardev ^f   Mclaughlin, Martin ^a   Harrington, Kevin J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ONCOLYTICS BIOTECH INC   (Canada)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; B RAF KINASE; CASPASE 3; CASPASE 7; DABRAFENIB; INITIATION FACTOR 2ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; ONCOLYTIC REOVIRUS TYPE 3; ONCOLYTIC VIRUS; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRAMETINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2-(2-CHLORO-4-IODOPHENYLAMINO)-N-CYCLOPROPYLMETHOXY-3,4-DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CASPASE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P21; SULFONAMIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMELANOMA ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; MELANOMA; METASTATIC MALIGNANT MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR VOLUME; TUMOR XENOGRAFT; UNFOLDED PROTEIN RESPONSE; UPREGULATION; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FIBROBLAST; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; REOVIRIDAE; TUMOR CELL LINE;

MAMMALIAN ORTHOREOVIRUS 3; ORTHOREOVIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FIBROBLASTS; HUMANS; INDOLES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; ONCOGENE PROTEIN P21(RAS); ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; REOVIRIDAE; SIGNAL TRANSDUCTION; SULFONAMIDES; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929048574     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.15     Document Type: Article

References (36)

1. Mandarà M, Nortilli R, Sava T and Cetto GL. (2006). Chemotherapy for metastatic melanoma. Expert Rev Anticancer Ther 6: 121-130
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949-954
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.; BRIM-3 Study Group. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516
4. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. (2012). Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11: 873-886
5. Chandra S and Pavlick AC. (2012). Targeted therapies for metastatic melanoma. Dermatol Clin 30: 517-524
6. Young K, Minchom A and Larkin J. (2012). BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol 8: 499-507
7. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714
8. da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, et al. (2013). The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 49: 1654-1661
9. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al.; METRIC Study Group. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107-114
10. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-1703
11. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-221
12. McArthur GA and Ribas A. (2013). Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol 31: 499-506
13. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. (2008). A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14: 7127-7137
14. Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, et al. (2010). Intravenous administration of Reolysin a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 28: 641-649
15. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, et al. (2012). Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 20: 1998-2003
16. Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, et al. (2010). REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16: 5564-5572
17. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, et al. (2011). A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17: 581-588
18. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, et al. (2012). Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 18: 2080-2089
19. Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, et al. (2013). Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther 20: 521-528
20. Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, et al. (2008). Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 14: 912-923
21. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, et al. (2009). Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 15: 6158-6166
22. Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, et al. (2009). Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 8: 47
23. Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, et al. (2011). Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 11: 221
24. Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, et al. (2014). Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-a signaling. Oncogene 33: 1700-1712
25. Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, et al. (2004). CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 18: 3066-3077
26. Carew JS, Espitia CM, Zhao W, Kelly KR, Coffey M, Freeman JW, et al. (2013). Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stressmediated apoptosis in pancreatic cancer. Cell Death Dis 4: e728
27. Jiang CC, Chen LH, Gillespie S, Wang YF, Kiejda KA, Zhang XD, et al. (2007). Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stressinduced apoptosis. Cancer Res 67: 9750-9761
28. Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, et al. (2012). Reovirus therapy stimulates endoplasmic reticular stress NOXA induction and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene 31: 3023-3038
29. Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW. (1998). The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362
30. Tabas I and Ron D. (2011). Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 13: 184-190
31. Hu, P, Han Z, Couvillon AD and Exton JH. (2004). Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J Biol Chem 279: 49420-49429
32. Jiang CC, Lucas K, Avery-Kiejda KA, Wade M, deBock CE, Thorne RF, et al. (2008). Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res 68: 6708-6717
33. Tay KH, Luan Q, Croft A, Jiang CC, Jin L, Zhang XD, et al. (2014). Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress. Cell Signal 26: 287-294
34. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, et al. (2005). A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307: 935-939
35. Tsaytler P, Harding HP, Ron D and Bertolotti A. (2011). Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 332: 91-94
36. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15: 294-303